Pirfenidone use in fibrotic diseases: What do we know so far?

ABSTRACT:

Background

Pirfenidone has demonstrated significant anti-inflammatory and antifibrotic effects in both animal models and some clinical trials. Its potential for antifibrotic activity positions it as a promising candidate for the treatment of various fibrotic diseases. Pirfenidone exerts several pleiotropic and anti-inflammatory effects through different molecular pathways, attenuating multiple inflammatory processes, including the secretion of pro-inflammatory cytokines, apoptosis, and fibroblast activation.

Objective

To present the current evidence of pirfenidone's effects on several fibrotic diseases, with a focus on its potential as a therapeutic option for managing chronic fibrotic conditions.

Findings

Pirfenidone has been extensively studied for idiopathic pulmon

SUBMITTER: Torre A 

PROVIDER: S-EPMC11225083 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature